1. South Korea Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Celltrion Pharm Inc.

Celltrion Pharm Inc.

KKRX:068760
37,600.00
KRW
-1,000.00
(-2.59%)
908.63EPS
60.31P/E
2.43TMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
2,444.27
3,205.17
2,561.04
2,829.46
3,073.66
3,314.89
3,918.64
5,369.24
8,984.6
8,701.12
8,757.55
10,770.01
12,347.05
12,552.76
Basic EPS, GAAP
121.29
281.86
-521.13
-569.77
61.42
-211.89
194.27
481.36
779.15
585.12
478.99
495.1
892
908.69
Free Cash Flow per Basic Share
-4,390.92
-851.18
-1,867.39
-834.6
-136.36
145.07
-94.87
-184.1
1,817.25
-232.87
41.86
1,140.6
1,576.93
1,183.31
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
7,754.87
7,900.51
6,610.18
6,580.54
6,763.58
6,089.8
6,626.49
6,908.86
7,707.75
8,442.53
8,916.51
9,400.89
9,842.34
9,824.68
Tangible Book Value per Share
5,625.42
5,810.54
5,276.07
5,617.18
5,844.34
5,281.97
5,766.04
6,034.2
6,792.26
7,464.7
7,986.38
8,472.66
8,866.88
8,438.18
Basic Weighted Avg Shares
22
21
29
37
44
44
44
44
44
44
44
44
43
44
Sales/Revenue/Turnover
52,657
66,744
74,732
104,811
135,860
146,880
173,513
233,568
398,738
386,040
388,794
477,835
536,400
555,998
Operating Margin (%)
14.23
12.51
-18.1
-14.32
6.38
2.43
8.49
10.12
11.99
9.89
9.28
7.79
10.46
10.48
Depreciation Expense
1,050
1,187
4,442
12,069
12,234
12,712
13,023
13,470
16,378
17,419
19,725
20,093
22,249
23,192
Net Income, GAAP
2,613
5,869
-15,207
-21,106
2,715
-9,389
8,602
20,940
34,579
25,960
21,265
21,966
38,752
40,248
Effective Tax Rate (%)
27.86
0.68
- -
- -
- -
- -
2.74
- -
18.68
14.8
18.86
26.19
22.05
22.69
Profit Margin (%)
4.96
8.79
-20.35
-20.14
2
-6.39
4.96
8.97
8.67
6.72
5.47
4.6
7.22
7.24
Working Capital
114,273
34,864
36,860
99,455
86,816
54,926
39,717
46,027
71,226
99,920
115,485
144,023
186,976
188,857
LT Debt
165,570
84,401
114,089
89,000
48,125
34,375
38,811
57,851
39,398
21,823
5,862
15,089
16,560
15,441
Total Equity
168,412
214,426
192,314
276,706
293,624
270,035
280,031
300,561
331,969
356,787
376,666
396,922
435,963
434,821
Return on Invested Capital (%)
1.82
2.27
- -
- -
- -
- -
3.34
- -
7.72
6.28
5.51
4.93
7.42
7.65
Return on Capital (%)
1.22
2.42
- -
- -
- -
- -
3.19
- -
7.74
6.07
5.3
4.96
7.54
7.76
Return on Common Equity (%)
1.6
3.07
-7.48
-9
0.95
-3.33
3.13
7.21
10.93
7.54
5.8
5.68
9.31
9.62

Capital Structure

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
153,526
144,755
145,140
LT Borrowings
- -
- -
- -
LT Finance Leases
17,223
16,560
15,441
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
44
44
44
Market Capitalization
2,323,154
2,569,092
2,425,343

Working Capital

KRW

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
464,496
470,598
481,571
Cash, Cash Equivalents & STI
122,762
116,929
133,914
Accounts Receivable, Net
204,845
220,287
209,060
Inventories
129,886
122,936
125,999
Total Current Liabilities
287,632
283,622
292,714
Payables & Accruals
- -
- -
- -
ST Debt
153,526
144,755
145,140
Deferred Revenue
- -
- -
- -

Growth Rates

KRW

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
9.17%
7.74%
9.84%
Free Cash Flow
91.54%
264.11%
35.38%
Net Income, GAAP
-46.63%
20.37%
76.42%
Sales/Revenue/Turnover
23.41%
20.68%
12.26%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
96,969
117,155
128,130
135,582
477,835
2025
112,524
131,298
138,175
154,404
536,400
2026
132,122
- -
- -
- -
- -

Quarterly Earnings Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
41.08
120.45
178.34
146.98
495.1
2025
161.76
250.36
258.71
200.54
892
2026
199.08
- -
- -
- -
- -

Quarterly Dividends Per Share

KRW

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Yeong-Ho Yu
Full Time Employees
888
Sector
Health technology
Industry
Pharmaceuticals: major
Address
Cheongju-si South Korea
IPO Date
Feb 3, 2006
Website
celltrionph.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Celltrion Pharm Inc. functions within the South Korean healthcare industry, specializing in the development and commercialization of a broad spectrum of pharmaceutical products. The company's key operations encompass manufacturing and distributing both biosimilars and over-the-counter medications. Its diverse portfolio includes hepatotonics, analgesics, anti-inflammatory and antipyretic compounds, antihistamines, respiratory treatments, circulatory system drugs, digestive aids, hormone-related medications, various antibiotics and antimycotics, as well as nutritional supplements and tonics. Celltrion Pharm Inc. primarily supplies its offerings to university hospitals and local pharmacies across South Korea, with a growing presence in certain overseas markets like the Philippines and Kazakhstan. As a subsidiary of Celltrion, Inc., it also provides contract manufacturing services, leveraging facilities that meet global quality standards.